Article successfully added.
CyFlow™ GCPII PE
| Application: | Flow cytometry |
| Clonality: | monoclonal |
| Target Species: | Human |
| Regulatory Status: | RUO |
| Laser: | Blue, Green, Yellow |
| Source Species: | Mouse |
| Format/Fluorochrome: | PE |
| Excitation Maximum: | 496 nm, 565 nm |
| Emission Maximum: | 576 nm |
| Isotype: | IgG1 |
| Field of Interest: | Neurobiology |
| Antigen: | GCPII |
| Alternative Name: | PSMA |
| Clone: | GCP-05 |
| Order number: | BR339703 |
For Research Use Only
Not for use in diagnostic or therapeutic procedures.
Concentration Unit mg/mL Concentration 0,1 Quantity 0.1 mg Volume 1.0 mL... more
Product information "CyFlow™ GCPII PE"
| Concentration Unit | mg/mL |
| Concentration | 0,1 |
| Quantity | 0.1 mg |
| Volume | 1.0 mL |
| Immunogen | Amino acids 44-750 of human GCPII |
| Background Information | Glutamate carboxypeptidase II (GCPII), also known as N-acetyl-α-linked acidic dipeptidase I (NAALADase I), folate hydrolase (FOLH1) and prostate-specific membrane antigen (PSMA), is an approximately 95-110 kDa type II transmembrane glycoprotein expressed in various tissues. In nervous system GCPII cleaves abundant N-acetylaspartylglutamate, which is released from neurons in a calcium-dependent manner, to N-acetylaspartate and glutamate. As immoderate glutamate concentration is neurotoxic, GCPII contributes to pathological conditions regarding e.g. Alzheimer´s disease, Huntington´s disease, epilepsy, schizophrenia, stroke or neuropathic pain and appears to be an interesting therapeutic target. In jejunum GCPII hydrolyzes pteroylpoly-γ-glutamate to folate and glutamate, enabling folate to be absorbed by gastrointestinal tract. GCPII, which is present in a number of tissues at low levels, is overexpressed in neovasculature of most solid tumors and is a target enzyme for diagnosis and treatment of prostate cancer. Normal human prostate express more mRNA coding for a cytosolic GCPII form truncated at the N-terminus (PSM´) than mRNA for membrane-bound GCPII, and this ratio is reversed upon malignant transformation. |
| Usage | The reagent is designed for Flow Cytometry analysis. Suggested working usage is 0.5·µg/ml. Indicated dilution is recommended starting point for use of this product, but working concentrations should be validated by the investigator. |
| Storage Buffer | The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
Technical Data Sheet
Similar products
FITC
CyFlow™ CD1a FITC
| Antigen: | CD1a |
| Clone: | SK9 |
| Application: | Flow cytometry |
| Regulatory Status: | RUO |
| Target Species: | Human | Quantity: | 100 tests |
PE
CyFlow™ CD1a PE
| Antigen: | CD1a |
| Clone: | SK9 |
| Application: | Flow cytometry |
| Regulatory Status: | RUO |
| Target Species: | Human | Quantity: | 100 tests |
APC
CyFlow™ CD1a APC
| Antigen: | CD1a |
| Clone: | SK9 |
| Application: | Flow cytometry |
| Regulatory Status: | RUO |
| Target Species: | Human | Quantity: | 100 tests |
Purified
CyFlow™ CD1a Purified
| Antigen: | CD1a |
| Clone: | SK9 |
| Application: | Flow cytometry, Immunoprecipitation |
| Regulatory Status: | RUO |
| Target Species: | Human | Quantity: | 0.1 mg |
FITC
CyFlow™ CD1b FITC
| Antigen: | CD1b |
| Clone: | SN13 |
| Application: | Flow cytometry |
| Regulatory Status: | RUO |
| Target Species: | Human | Quantity: | 100 tests |
Purified
CyFlow™ CD1b Purified
| Antigen: | CD1b |
| Clone: | SN13 |
| Application: | Flow cytometry, Immunohistochemistry, Immunoprecipitation |
| Regulatory Status: | RUO |
| Target Species: | Human | Quantity: | 0.1 mg |
PE
CyFlow™ CD1c PE
| Antigen: | CD1c |
| Clone: | L161 |
| Application: | Flow cytometry |
| Regulatory Status: | RUO |
| Target Species: | Human | Quantity: | 100 tests |
Purified
CyFlow™ CD1c Purified
| Antigen: | CD1c |
| Clone: | L161 |
| Application: | Flow cytometry, Immunohistochemistry, Immunoprecipitation |
| Regulatory Status: | RUO |
| Target Species: | Human | Quantity: | 0.1 mg |